ACAD earnings: real EPS beat/miss history, analyst consensus Buy, P/E 11.19. Updated 2026-07-23.
ACADIA Pharmaceuticals (ACAD) Research Hub
ACADIA Pharmaceuticals (ACAD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 27.83 USD (+0.54%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 11.19, market cap 4.28B. This hub links to the full technical, earnings and options research available for ACAD.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 27.83 USD (+0.54%) |
| 52-week range | 20.92 USD – 30.96 USD |
| Trend regime | Range |
| 14-day RSI | 41.8 (Bearish) |
| Trailing P/E | 11.19 |
| Market cap | 4.28B |
| Dividend yield | 0.00% |
Available research for ACAD
Covered Call on ACAD: how it works, illustrative setup around the real 27.83 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACAD: how it works, illustrative setup around the real 27.83 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACAD: how it works, illustrative setup around the real 27.83 USD price, max profit/loss, breakeven and when to use it. Educational.
ACAD technical analysis: range, last 27.83 USD, RSI 41.8, 52w range 20.92 USD–30.96 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ACAD in?
ACADIA Pharmaceuticals (ACAD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACAD in an uptrend or downtrend?
As of 2026-09-11, ACAD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACAD's trailing P/E ratio?
ACAD's trailing P/E is 11.19, with a market cap of 4.28B. See the earnings research page for full valuation detail.